Kimyrsa (Oritavancin Diphosphate) Patent Expiration, LOE Window & CMS Spending

Kimyrsa (Oritavancin Diphosphate) by Melinta Therapeutics: FDA Orange Book core substance LOE 2035-07-16, 0 AB generics, $1.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMelinta Therapeutics
FDA Application & PathwayN214155 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-07-16
Last Listed Patent or Exclusivity Date2035-07-16
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.8M
2024 Medicare Part D Spend$649K
2024 Medicaid Spend$1.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel